Evidence map›Paper›PMID 27622300›Full record

ArticleVaccine2016

Preclinical identification of vaccine induced protective correlates in human leukocyte antigen expressing transgenic mice infected with Coccidioides posadasii.

Brady J Hurtgen, Natalia Castro-Lopez, Maria Del Pilar Jiménez-Alzate, Garry T Cole, Chiung-Yu Hung

Abstract read
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. The Host Response to Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Brady J HurtgenDepartment of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas, San Antonio, TX, USA; Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, TX, USA.
Natalia Castro-LopezDepartment of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas, San Antonio, TX, USA.
Maria Del Pilar Jiménez-AlzateDepartment of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas, San Antonio, TX, USA; Grupo de Micología Médica, Department of Microbiology and Parasitology, School of Medicine, Universidad de Antioquia, Medellín, Colombia.
Garry T ColeDepartment of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas, San Antonio, TX, USA; Department of Microbiology and Immunology, University of Texas Health Science Center at San Antonio, TX, USA.
Chiung-Yu HungDepartment of Biology and South Texas Center for Emerging Infectious Diseases, University of Texas, San Antonio, TX, USA; Immune Defense Core, University of Texas, San Antonio, TX, USA. Electronic address: Chiungyu.Hung@UTSA.edu.
Texas Center for Infectious Disease · USThe University of Texas Health Science Center at San Antonio · USUniversidad de Antioquia · CO

Funding

Development of a multivalent vaccine against Coccidioides infectionR01AI135005 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI HUNG, CHIUNG-YU · 2018 to 2022
$1.9M
A Recombinant Protein Vaccine Against CoccidioidomycosisR01AI071118 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI COLE, GARRY THOMAS · 2008 to 2012
$1.8M
Enhancement of protective efficacy of Coccidioides vaccines by adjuvantsR21AI114762 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI HUNG, CHIUNG-YU · 2015 to 2016
$439k
NIAID NIH HHS R01 AI071118NIAID NIH HHS R01 AI135005NIAID NIH HHS R21 AI114762
6 · The paper itself

Abstract

There is an emerging interest to develop human vaccines against medically-important fungal pathogens and a need for a preclinical animal model to assess vaccine efficacies and protective correlates. HLA-DR4 (DRB1∗0401 allele) transgenic mice express a human major histocompatibility complex class II (MHC II) receptor in such a way that CD4

Indexed as

Adaptive ImmunityAnimalsCoccidioidesCoccidioidomycosisCytokinesFungal VaccinesHLA-DR4 AntigenHumansImmunity, InnateLungMiceMice, Inbred C57BLMice, TransgenicSpores, FungalTh17 CellsVaccines, AttenuatedCytokinesFungal VaccinesHLA-DR4 AntigenVaccines, AttenuatedCoccidioidesCoccidioidomycosisFungal vaccineHLA-DR4 transgenic miceInnate and adaptive immunity

Identifiers

PMID27622300
PMCPMC5053907
OpenAlexW2519103352

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.